Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reckitt Bids Up Bayer With $1.4 Bil. Schiff Nutrition Offer

This article was originally published in The Tan Sheet

Executive Summary

Reckitt Benckiser’s $1.4 billion offer to acquire Schiff Nutrition would be 23.5% higher than Bayer’s and more than an 80% premium over Schiff’s share price prior to the Bayer announcement. Gaining Schiff would expand Reckitt’s consumer health business beyond OTC drugs and represent its first supplement foray.

You may also be interested in...



New Chapter Taps Into P&G Product Development Capacity

Six months after becoming a wholly owned subsidiary of Procter & Gamble, dietary supplement firm New Chapter is taking advantage of its parent company’s resources in innovation, ingredient sourcing, clinical trials and packaging, says New Chapter VP Graham Rigby.

Reckitt Reorganizes To Develop Health Care, Emerging Markets

Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.

Topics

Related Companies

UsernamePublicRestriction

Register

PS106094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel